



March 30, 8:30 am – 6:00 pm  
Alexandria Center for Life Science  
450 E 29<sup>th</sup> Street, New York City

**INVITATION ONLY – FINAL AGENDA as of 03/06/2023 (subject to change)**

8:30 – 9:00

**Breakfast followed by Opening Remarks from ACGT Leadership**

- Barbara Lavery, Chief Program Officer
- Michael T. Lotze, MD, Chair, Scientific Advisory Council

9:00 – 10:00

**Fireside Chat: *Creating the perfect storm to treat cancer - combining cell therapies, checkpoint inhibitors, antibodies, and bi-specifics to deliver the best possible therapeutic options for patients***

- George D. Yancopoulos, MD, PhD, Scientific Founder, President and Chief Scientific Officer, Regeneron Pharmaceuticals
- Ira Mellman, PhD, VP Cancer Immunology, Genentech

**MODERATOR:** Gregory C. Simon, former President, Biden Cancer Initiative

10:00 – 10:15

**BREAK**

10:15 – 11:30

**ACGT Fellows Presentations & Discussion**

**Macrophage-targeting CAR T Cells**

- Brian Brown, PhD, Icahn School of Medicine at Mount Sinai

**PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer**

- Vivek K. Nayaran, MD, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania (standing in for Joseph Fraietta, PhD, ACGT Fellow)

11:30

**BREAK** (Transition to ACGT AWARDS LUNCHEON downstairs at RIVERPARK Restaurant)



ALLIANCE for CANCER GENE THERAPY

## AWARDS LUNCHEON

11:30 – 1:30

**Special Keynote Guest Siddhartha Mukherjee**

**Receiving the *Edward Netter Leadership Award*, Crystal L. Mackall, MD, Stanford University, presented by Carl H. June, MD**

1:30 – 2:15

**ACGT Collaboration Highlight: Parker Institute for Cancer Immunotherapy, Cancer Research Institute and ACGT**

**BRUCE: *BR*ain *tU*mor heterogeneity de*C*iphered by high dim*E*nsional multi-omic analysis**

Designed to identify new targets for the treatment of pediatric and adult aggressive brain tumors with immunotherapy, this collaboration among PICI and researchers at City of Hope, Children's Hospital of Philadelphia, Stanford, UCLA and UCSF, is in partnership with the Cancer Research Institute and the Alliance for Cancer Gene Therapy. As the project moves into its third year, we take a look at emerging patterns resulting from the analysis of 532 tumor cores from 162 patients.

- **EXPERT PANELISTS:** John Connolly, Chief Scientific Officer, The Parker Institute; Michael Angelo, MD PhD, Stanford University; Robert M. Prins, PhD, UCLA

**MODERATOR:** Barbara Lavery, Chief Program Officer, ACGT

2:15-2:30

**BREAK**

2:30 – 4:30

**Expert Panels & Collaborative Discussions - An interactive setting allowing participants to hear from leaders in the field, address specific cancer challenges and discuss collaborative solutions with their peers.**

**CELL AND GENE THERAPIES FOR PEDIATRIC CANCERS:** While immunotherapy can be successful in treating leukemia and neuroblastoma, there are currently no effective immunotherapy options for most patients with high-risk or difficult-to-treat childhood cancers. Unlike many adult tumors, many childhood cancers express few or no markers that can be recognized by the immune system. Also, many immunotherapies under development target specific markers that are expressed in adult cancers but not childhood cancers.

This interactive session is intended to identify the challenges and opportunities in developing cell and gene therapies for pediatric cancers and to encourage collaboration across academia, industry and philanthropy to advance cell and gene therapies for children and young adults who currently have limited treatment options.

- **EXPERT PANELISTS:** Stephen Gottschalk, MD, St. Jude Children's Research Hospital; Crystal Mackall, MD, Stanford University; E. Antonio Chiocca, MD, PhD, Brigham and Women's Hospital

**MODERATOR:** Lucas De Breed, Director, Investments – BrightEdge, American Cancer Society

- **THE EXPANDING CELL & GENE THERAPY UNIVERSE:** As we move beyond the “big bang” of the initial CAR T-cell therapy breakthroughs, the possibility of cells and genes as medicine is expanding and becoming ever more complex. What are the opportunities in combining emerging platforms (NK cells, Myeloid cells, Gamma Delta T cells, CAR T cells, TILs, oncolytic viruses and TCRs) to meet the complexity of cancers and their microenvironments?

This interactive session is intended to identify opportunities in combining cell and gene therapeutic approaches and to encourage collaboration across the full spectrum of emerging technologies and therapeutic platforms. (Synthetic biology, nanotechnology, emerging cellular platforms)

- **EXPERT PANELISTS:** Carl June, MD, University of Pennsylvania; Steven Thorne, PhD, Kalivir; Stephen Russell, MD, PhD, Vyriad; Michael T. Lotze, MD, Nurix Therapeutics.

**MODERATOR:** Gbola Amusa, MD, Partner and Chief Scientific Officer, Chardan

4:30 – 5:00

**Announcing the ACGT Collaboration Challenge**

The ACGT Summit 2023 will launch an ACGT Collaboration Challenge open to Fellows and alliance members in attendance. The ACGT Collaboration Challenge will focus on funding cross-functional teams from academia, biotech and cancer-focused non-profits to advance cell and gene therapies for cancer.

- Barbara Lavery, Chief Program Officer, ACGT.

5:00 – 6:00

**Networking Reception**

Attendees can continue to develop collaborations and creative thinking over a beverage and light hors d'oeuvres.